ストックスクリーナーアプリを入手
31.60
2.95%
-0.96
前日終値:
$32.56
開ける：
$32.31
24時間の取引高:
1.07M
Relative Volume:
0.83
時価総額：
$4.00B
収益：
$10.12M
当期純損益:
$-280.49M
株価収益率:
-10.93
EPS:
-2.89
ネットキャッシュフロー:
$-188.51M
1週間 パフォーマンス:
+2.46%
1か月 パフォーマンス:
+8.67%
6か月 パフォーマンス:
-25.35%
1年 パフォーマンス:
+23.82%
1日の値動き範囲:
$31.15
$32.68
1週間の範囲:
$31.01
$33.79
52週間の値動き範囲:
$21.56
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
名前
Avidity Biosciences Inc
セクター
電話
858-401-7900
住所
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
31.60 | 4.00B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-09-24 | 開始されました | Goldman | Buy |
| 2024-08-28 | 開始されました | Barclays | Overweight |
| 2024-05-03 | 開始されました | BofA Securities | Buy |
| 2024-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-05-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-31 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Strong Buy |
| 2021-09-07 | 開始されました | Evercore ISI | Outperform |
| 2021-06-17 | 開始されました | Needham | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | Cowen | Outperform |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | SVB Leerink | Outperform |
| 2020-07-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Avidity Biosciences Inc (RNA) 最新ニュース
The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha
Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia
Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise
Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia
Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com India
Avidity Biosciences chief medical officer sells $297,490 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com
Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com
Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView
Avidity Biosciences CFO Michael MacLean sells $246,424 in stock - Investing.com
Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com
Avidity Biosciences Signals Growth: Awards 152K Shares to 16 New Hires - StockTitan
H.C. Wainwright maintains $72 target on Avidity Biosciences stock By Investing.com - Investing.com Canada
Forecasting The Future: 13 Analyst Projections For Avidity Biosciences - Benzinga
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Yahoo
New Duchenne Results Put Avidity On Course For Filing - News & Insights
Avidity Biosciences reports progress in DMD treatment trial By Investing.com - Investing.com Australia
Citi maintains $70 target on Avidity Biosciences stock post-trial By Investing.com - Investing.com Canada
Avidity eyes 2025 BLA on back of positive DMD data - BioWorld Online
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 - Benzinga India
Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks
Avidity Biosciences reports progress in DMD treatment trial - Investing.com India
Avidity Biosciences Announces Positive EXPLORE44 Trial Results - TipRanks
Avidity Biosciences Announces Positive Topline Del-Zota Data In DMD44 Trial -March 17, 2025 at 07:12 am EDT - Marketscreener.com
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skip - Financial Times
Bank of New York Mellon Corp Buys 59,295 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
BMO Capital Markets Begins Coverage on Avidity Biosciences (NASDAQ:RNA) - Defense World
Citigroup Initiates Coverage of Avidity Biosciences (RNA) with Buy Recommendation - Nasdaq
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - The Malaysian Reserve
Avidity Biosciences Stock Climbs Amid Promising Prospects - TipRanks
Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth By Investing.com - Investing.com South Africa
BMO Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform Recommendation - MSN
Avidity Biosciences chief scientific officer sells $602,614 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences Announces Upcoming Presentations at the Musc - GuruFocus.com
Avidity Biosciences chief scientific officer sells $602,614 in stock - Investing.com India
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference – Company AnnouncementFT.com - Financial Times
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Benzinga India
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Avidity Biosciences to Participate in Upcoming Investor Conferen - GuruFocus.com
BMO starts coverage on Avidity with 'outperform', says first-in-disease therapies in sight - TradingView
BMO Capital Initiates Avidity Biosciences at Outperform With $72 Price Target -March 12, 2025 at 07:10 am EDT - Marketscreener.com
Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth - Investing.com India
BMO CAPITAL INITIATES AVIDITY BIOSCIENCES WITH OUTPERFORM RATING By Investing.com - Investing.com UK
Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $48.00 by Analysts at Bank of America - Defense World
Scotiabank Initiates Coverage of Avidity Biosciences (RNA) with Sector Outperform Recommendation - MSN
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Contrasting Teva Pharmaceutical Industries (NYSE:TEVA) and Avidity Biosciences (NASDAQ:RNA) - Defense World
Scotiabank Initiates Coverage on Avidity Biosciences (NASDAQ:RNA) - Defense World
Principal Financial Group Inc. Has $275,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences Inc (RNA) 財務データ
収益
当期純利益
現金流量
EPS
Avidity Biosciences Inc (RNA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Mar 20 '25 |
Sale |
31.06 |
31,540 |
979,563 |
305,871 |
| Flanagan W. Michael | Chief Scientific Officer |
Mar 20 '25 |
Sale |
31.06 |
11,780 |
365,868 |
80,195 |
| MacLean Michael F | Chief Financial Officer |
Mar 20 '25 |
Sale |
31.06 |
7,935 |
246,425 |
96,720 |
| McCarthy Teresa | Chief Human Resources Officer |
Mar 20 '25 |
Sale |
31.06 |
7,778 |
241,583 |
97,130 |
| Flanagan W. Michael | Chief Scientific Officer |
Mar 11 '25 |
Option Exercise |
14.22 |
20,000 |
284,400 |
111,975 |
| Flanagan W. Michael | Chief Scientific Officer |
Mar 11 '25 |
Sale |
30.13 |
20,000 |
602,614 |
91,975 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):